• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Esperion Theraptc (NQ: ESPR )

    2.410 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 105
    Open 2.410
    Bid (Size) 2.390 (2)
    Ask (Size) 2.490 (20)
    Prev. Close 2.410
    Today's Range 2.410 - 2.410
    52wk Range 0.7000 - 3.400
    Shares Outstanding 28,277,493
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -17.47%
    -17.47%
    1 Month
    +10.55%
    +10.55%
    3 Month
    +26.18%
    +26.18%
    6 Month
    +12.09%
    +12.09%
    1 Year
    +63.95%
    +63.95%

    More News

    Read More
    Wall Street's Top 10 Stock Calls This Week - Saturday, June 22
    Via Talk Markets
    Workday To Rally Over 52%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Stocks to Buy: 3 Biotech Bargains Delivering Breakthroughs on a Budget
    Via InvestorPlace
    3 Penny Stocks to Buy if You Want to Spend Less and Earn More
    Via InvestorPlace
    Why Skye Bioscience Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Argan Reports Strong Earnings, Joins Geron, Planet Labs PBC And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    Esperion to Participate in Upcoming June Investor Conferences
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion Therapeutics/Otsuka Partnered Cholesterol Drug Shows Effective In Japan Study
    Via Benzinga
    Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS
    Via AB Newswire
    ESPR Stock Earnings: Esperion Therapeutics Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
    Via Benzinga
    Exposures Product Safety
    Why Is AgriFORCE Growing (AGRI) Stock Down 31% Today?
    Via InvestorPlace
    Why Is GreenPower Motor (GP) Stock Down 36% Today?
    Via InvestorPlace
    Why Is Esperion Therapeutics (ESPR) Stock Up 13% Today?
    Via InvestorPlace
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Via InvestorPlace
    Esperion Reports First Quarter 2024 Financial Results
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion to Participate in Upcoming May Investor Conferences
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.